Assessment of renal function in patients with myositis and treated with subcutaneous immunoglobulin: a series of 24 cases

Chérìn, P.; Tadmouri, Abir; Jaeger, Christophe; Sala, Taylor Pindi; Crave, Jean-Charles

doi:10.1177/1759720x18787765

Cited by 3 publications

(1 citation statement)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Some precautionary measures have been proposed to reduce the risk of osmotic nephrosis, including using the lowest effective dose, slowing the rate of infusion, adequate hydration of the patient, suspension of nephrotoxic drugs and, interestingly, use of subcutaneous formulation, due to its pharmacokinetic profile which insures a slower increase of peak IgG quantity in blood 15 16…”

Section: Discussionmentioning

confidence: 99%

Rare case of interstitial nephritis in a young adult under IgG therapy

et al. 2022

View full text Add to dashboard Cite

Immunoglobulin replacement therapy is an important therapeutic approach used in different diseases, such as immunodeficiency diseases. We report a case of a 19-year-old female patient with suspected common variable immunodeficiency who started replacement therapy with IgG. During the follow-up, she developed interstitial nephritis and the subsequent workup excluded other diseases or triggers except IgG therapy.

show abstract

Section: Discussionmentioning

confidence: 99%

Rare case of interstitial nephritis in a young adult under IgG therapy

et al. 2022

View full text Add to dashboard Cite

show abstract

Immunoglobulin treatment for B-cell immunodeficiencies

Freeman

Squire

Joshi

2022

Journal of Immunological Methods

View full text Add to dashboard Cite

Immune globulin therapy and kidney disease: Overview and screening, monitoring, and management recommendations

Kobayashi

Rigas

2022

American Journal of Health-System Pharmacy

View full text Add to dashboard Cite

Disclaimer In an effort to expedite the publication of articles related to the COVID-19 pandemic, AJHP is posting these manuscripts online as soon as possible after acceptance. Accepted manuscripts have been peer-reviewed and copyedited, but are posted online before technical formatting and author proofing. These manuscripts are not the final version of record and will be replaced with the final article (formatted per AJHP style and proofed by the authors) at a later time. Purpose This report calls attention to the potential risks of diminished kidney function when administering immune globulin (IG). The goal is to increase awareness of chronic kidney disease (CKD) and kidney function impairment in patients receiving IG and provide recommendations for screening, monitoring, and management to promote risk prevention and mitigation. Summary Human IG preparations for intravenous (IVIG) or subcutaneous (SCIG) administration are the mainstay of treatment in patients with primary immunodeficiency diseases. Increasingly, IVIG at high doses (1,000 to 2,400 mg/kg) is also used as a treatment for a variety of autoimmune and inflammatory conditions. Although some autoinflammatory disorders respond to a single course of IVIG therapy, the majority of patients require long-term, regular infusions, thereby increasing the overall risks. Often, both patients and physicians treating adults with IG are unaware of underlying CKD or kidney function impairment. This lack of awareness constitutes a major risk factor for potential worsening, particularly when using high doses of IVIG. Therefore, screening of all patients for CKD and kidney function impairment before the use of IG is essential. Identification of the cause of kidney impairment is strongly encouraged, as IG therapy may need to be modified. Conclusion As detailed here, there are potential risks to patients with impaired kidney function with administration of IG, particularly at high doses. Product selection, volume, route of administration, and rate of infusion may impact those with compromised kidney function. Therefore, screening of all patients for CKD and kidney function impairment before the use of IVIG and SCIG, as well as ongoing monitoring and management, is critical. As with all potential adverse drug reactions, the best approach is to prevent them.

show abstract

Assessment of renal function in patients with myositis and treated with subcutaneous immunoglobulin: a series of 24 cases

Cited by 3 publications

References 24 publications

Rare case of interstitial nephritis in a young adult under IgG therapy

Rare case of interstitial nephritis in a young adult under IgG therapy

Immunoglobulin treatment for B-cell immunodeficiencies

Immune globulin therapy and kidney disease: Overview and screening, monitoring, and management recommendations

Contact Info

Product

Resources

About